1. Home
  2. YDES vs PCRX Comparison

YDES vs PCRX Comparison

Compare YDES & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YDES

YD Bio Limited Ordinary Shares

N/A

Current Price

$11.97

Market Cap

1.1B

Sector

N/A

ML Signal

N/A

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$25.74

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YDES
PCRX
Founded
2013
2006
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
YDES
PCRX
Price
$11.97
$25.74
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$32.86
AVG Volume (30 Days)
110.9K
656.9K
Earning Date
09-30-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.47
Revenue
$510,360.00
$716,791,000.00
Revenue This Year
N/A
$6.24
Revenue Next Year
N/A
$9.53
P/E Ratio
N/A
$54.59
Revenue Growth
45.76
3.14
52 Week Low
$5.30
$18.17
52 Week High
$31.00
$27.64

Technical Indicators

Market Signals
Indicator
YDES
PCRX
Relative Strength Index (RSI) N/A 69.20
Support Level N/A $23.63
Resistance Level N/A $24.81
Average True Range (ATR) 0.00 0.92
MACD 0.00 0.20
Stochastic Oscillator 0.00 85.75

Price Performance

Historical Comparison
YDES
PCRX

About YDES YD Bio Limited Ordinary Shares

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: